A novel artificial lung organoid for simulating a patient derived adenocarcinoma of lung for personalized oncology.
Esmail, S.; Danter, W. R.
Show abstract
Optimizing patient care based on precision oncology will inevitably become the standard of care. If we accept the principle that every persons cancer is different then the most effective therapies will have to be designed for the individual patient and for their tumors genetic profile. Access to tumor mutational profiling is now widely available but continues to be limited by cost and actionable information. For example, novel combinations of approved drugs are rarely considered. These considerations lead us to hypothesize that artificially induced Lung Adenocarcinoma (LUAD) derived lung organoids could provide a novel, alternate approach for LUAD disease modeling and large-scale targeted drug screening. In this project, we used data from a commercially available tumor mutation profile to generate and then validate the artificially induced LUAD-derived lung organoid simulations (aiLUNG-LUAD) to model LUAD and identify several drug combinations that effectively reverse the tumors genotypic and phenotypic features when compared with placebo. These results complement previous LUAD-derived lung organoids research and provide a novel and widely applicable cancer drug-screening approach for precision/individualized oncology.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- An algorithm for drug discovery based on deep learning with an example of developing a drug for the treatment of lung cancer 92%
- Interactive, visual simulation of a spatio-temporal model of gas exchange in the human alveolus 91%
- Reliable machine learning models in genomic medicine using conformal prediction 91%
Similar papers in this journal
- Methodological Challenges in Translational Drug Response Modeling in Cancer 93%
- TranSynergy: Mechanism-Driven Interpretable Deep Neural Network for the Synergistic Prediction and Pathway Deconvolution of Drug Combinations 93%
- Computational design of improved standardized chemotherapy protocols for grade II oligodendrogliomas 93%
Similar papers in this journal
- Machine learning for prediction of immunotherapy efficacy in non-small cell lung cancer from simple clinical and biological data 91%
- Dynamic PD-L1 Regulation Shapes Tumor Immune Escape andResponse to Immunotherapy 91%
- Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanoma 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.